Corporate Presentation

NASDAQ: CRIS

Forward Looking Statements

This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “believe(s),” “will,” “may,” “anticipate(s),” “focus(es),” “plans,” “mission,” “strategy,” “potential,” “estimate(s)”, "intend," "project," "seek," "should," "would" and similar expressions are intended to identify forward-looking statements. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this presentation, and involve important risks and uncertainties. Forward-looking statements herein include, but are not limited to, statements with respect to the timing and results of future clinical and pre-clinical milestones; the timing of future preclinical studies and clinical trials and results of these studies and trials; the clinical and therapeutic potential of our drug candidates; and management’s ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of important factors including, without limitation, risks relating to: whether any of our drug candidates will advance further in the clinical development process and whether and when, if at all, they will receive approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies; whether historical preclinical results will be predictive of future clinical trial results; whether historical clinical trial results will be predictive of future trial results; whether any of our drug candidate discovery and development efforts will be successful; whether any of our drug candidates will be successfully marketed if approved; our ability to achieve the benefits contemplated by our collaboration agreements; management’s ability to successfully achieve its goals; the sufficiency of our cash resources; our ability to raise additional capital to fund our operations on terms acceptable to us or the use of proceeds of any offering of securities or other financing; general economic conditions; competition; and the other risk factors contained in our periodic and interim reports filed with the Securities and Exchange Commission which are available on the SEC website at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events, except as required by law.

Curis Mission & Strategy

Developing the New Generation of Targeted Cancer Drugs



Mission

Help patients suffering with cancer to live longer and healthier lives

Strategy

Select the right targets
Design the right drugs
Study the right patients

Overview

Investment Thesis	Curis seeks to develop novel, first-in-class, cancer therapeutics that we believe have significant potential in areas of unmet patient need
Robust Pipeline	Fimepinostat: first-in-class suppressor of MYC *There are no drugs currently approved for MYC inhibition* CA-4948: first-in-class suppressor of the TLR Pathway *There are no drugs currently approved that block the entire TLR pathway* CA-170*: first-in-class suppressor of VISTA *There are no drugs currently approved for VISTA inhibition*
Corporate	• Experienced management team with proven capabilities • Curis R&D pioneered the FDA-approved, first-in-class suppressor of the Hedgehog pathway (Erivedge®) partnered with and commercialized by Genentech and Roche for advanced basal cell carcinoma in adults • Cash, cash equivalents and investments of approximately $28M as of Sept 30, 2019

**Based on initial data no further patients will be enrolled in the study. We are currently evaluating future studies for CA-170.*

Evolution of Curis

Progressing through Clinical Studies on the Path to Potential Registration



**Based on initial data no further patients will be enrolled in the study. We are currently evaluating future studies for CA-170.*

Pipeline of Oncology Drug Candidates



* IP licensed from Aurigene

** IP licensed to Genentech (Curis receives royalty income)

Targeted Programs in Heme Malignancies

Fimepinostat: In development for treatment of MYC-altered cancers

Fimepinostat Overview

In development for patients with MYC-altered cancers

	Profile
Value Proposition	• First-in-class drug candidate with demonstrated anti-cancer activity as a monotherapy in MYC-altered patients in Phase 1 and Phase 2 trials • Composition-of-matter IP extends into 2032
Population	• Patients with MYC-altered cancer (>50% of all cancers are effected by MYC)[3]
Product Candidate Description	• Potent and orally bioavailable dual inhibitor of HDAC and PI3K enzymes[1] • Favorable safety profile in over 200 patients



Protein levels in DLBCL cells after treatment with Fimepinostat (Curis Preclinical Study)

1) Qian et.al. Clin Cancer Res. 2012. 18: 4104
2) Sun et.al. Mol Cancer Ther. 2017. 6: 285
3) Chen et al. Nature. 2018 Feb 23. 3:5

Clinical data provides strong rationale for development in MYC-altered lymphoma



Monotherapy Anti-Cancer Activity

Deep responses

- 8 complete responses (CR); 6 partial responses (PR)
- 2 patients able to proceed to transplant

Durable responses

- Median duration = 13.6 months

Fast Track designation received

- Following FDA review of clinical data

Fimepinostat + venetoclax appear highly synergistic in preclinical models

Fimepinostat + Venetoclax As Combination Therapy Partners

Active single-agents in DLBCL

Fimepinostat = 23% ORR with 13.6 month DOR[1]

Venetoclax = 18% ORR[2]

Highly synergistic combination

- Combination index of < 0.1 at multiple doses[3]

High unmet need

NCCN: Double-hit lymphoma (DHL) is poor outcome group

FDA: DHL is high unmet need

Regulatory path

- Potential for accelerated approval in DHL or other orphan indications
- Potential for full approval with randomized controlled trial

Fimepinostat + Venetoclax Appear Highly Synergistic in Preclinical Studies

(DH DOHH-2 DLBCL model)[4]



1) 14 PR/CR out of 60 patients in Ph1 & Ph2 (23% ORR)
2) Davids et al. JCO. 2017. 35:826
3) Booher et al. ASH 2016 (poster #4184)
4) Data from Curis preclinical study

Phase 1 combination study designed to demonstrate safety of combination

Patient Population

- Patients with R/R DLBCL, including DH/DE Lymphoma
- 8 Study Sites (US only)

Treatment

Fimepinostat: Oral daily (5 days on, 2-days off)
Venetoclax: Oral daily (with rapid dose ramp-up)

Objective

- Safety/tolerability during dose escalation
- Efficacy during expansion



Preliminary Phase 1 Tolerability Data Readout

- Generally well tolerated
- No drug-drug interaction that required dose modification of either agent

Targeted Programs in Heme Malignancies

CA-4948: In development for treatment of TLR-altered cancers

CA-4948 Overview

In development for patients with MYD88/TLR-altered disease

Profile	
Value Proposition	• First-in-class IRAK4 inhibitor in cancer • Specific malignancies have overactivity of the myddosome/TLR pathway (dependent upon IRAK4) • Composition-of-matter IP extends into 2035
Population	Lymphoma: IRAK4-dependent pathway activated; Ibrutinib-treated patients (strong synergy) Leukemia: Tumors with splicing mutations that overexpress IRAK4
Product Candidate Description	• Potent and orally bioavailable inhibitor of IRAK4 for treatment of MYD88-altered tumors and augmentation of BTK inhibition

Designed to be best-in-class IRAK4 inhibitor[1]

	Affinity
Kinase	K_d (nM)
IRAK4	23
IRAK1	12,000
IRAK2	>20,000
IRAK3	8,500

Potent suppressor of signal transduction[2]



Phospho-protein levels in AML cells after treatment with CA-4948

1) Data from Curis preclinical study
2) Booher et al. AACR 2017 (poster #1168)

Mechanism of Action

In development for patients with MYD88/TLR-altered disease

Inhibiting either of these two pathways should provide benefit to patients with B cell lymphoma, CA-4948 targets oncogenic activity in the TLR pathway by blocking IRAK4

Oncogenic
- Dysregulation drives excessive B Cell proliferation

Pathway validated
- Waldenström's macroglobulinemia[1]
- MCL, MZL, CLL

BTK inhibition effective
- Ibrutinib is FDA approved



Oncogenic
- Dysregulation drives excessive B cell proliferation[2,3]

Dependent upon IRAK4
- Signaling requires myddosome, which requires IRAK4

Strong Synergy
- Inhibition highly synergistic with BTK inhibition

1) IMBRUVICA Package Insert. Rev 08/2018
2) Ngo et al. Nature. 2011 Feb 3;470(7332):115-9
3) Küppers et al. J Exp Med. 2015. 212(13): 2184
4) Smith et al. Nat Cell Biol 2019

Potent preclinical anti-cancer activity

in MYD88-altered DLBCL models

Anti-cancer activity in MYD88-altered DLBCL[1]

(OCI-Ly10)



Preclinical Anti-Cancer Activity

Potent as monotherapy

- Anti-cancer activity demonstrated in MYD88-altered DLBCL

Strong Synergy

- Anti-cancer activity demonstrated to be highly synergistic with BTK inhibition

1) Data from Curis preclinical study; Booher, et al. 4th Waldenstrom Roadmap Symposium

CA-4948 Phase 1 Study to date in R/R Lymphoma

Preliminary clinical data demonstrate safety, PK, PD, and anti-cancer activity



Preliminary Phase 1 Data Readout

- Generally well tolerated
- Favorable PK profile; PD and anti-cancer activity
- 5 of 6 patients at 200mg-400mg cohorts have seen reduction

Patient Population

- Patients with R/R Lymphoma (incl DLBCL, WM, and patients with MYD88-altered disease)

Treatment

- Oral, once-daily (QD) or twice-daily (BID), dosing in continuous 21-day cycles

Objective

- Safety/tolerability during dose escalation
- Efficacy during expansion

CA-4948 Phase 1 Study in R/R Lymphoma

Dose response observed as study enrolls at therapeutic dose levels





* 3 patients are too early for evaluation; 1 patient considered not evaluable for efficacy due to dose limiting toxicity on day 4

Dose Response Observed

5 of 6 patients see tumor reduction as dose increased to therapeutic levels (200mg-400mg)

CA-4948 Phase 1 Study in R/R Lymphoma

Dose response observed as study enrolls at therapeutic dose levels



Dose Response Observed
increased tumor reduction observed as patient increased dose

Small Molecule Immune Checkpoint Inhibitor

CA-170: In development for treatment of VISTA/PDL1-expressing cancers

CA-170 Overview

In development for patients with VISTA/PDL1-expressing cancers

Curis is the first to advance an oral small molecule checkpoint inhibitor into the clinic

Profile	
Value Proposition	• First-in-class oral inhibitor of VISTA • Only anti-VISTA drug in the clinic • Composition-of-matter IP through 2034
Population	• Patients with VISTA-expressing cancers, including Mesothelioma, NSCLC, and TNBC • Patients whose disease progresses after treatment with immune checkpoint therapy
Product Description	• Orally available, small molecule targeting VISTA and PD-L1 immune checkpoints • Favorable safety profile demonstrated in 59 patients[2]

CA-170 binds to the receptor-ligand interaction site



Dose dependent activation of VISTA or PDL1inhibited human T cells *ex-vivo*[1]



IFN-γ production used as a marker for T cell activation

1) Lazorchak et al. AACR 2016
2) Data from Ph1 (NCT02812875) study

Summary

Investment Thesis	Curis seeks to develop novel, first-in-class, cancer therapeutics that we believe have significant potential in areas of unmet patient need
Robust Pipeline	Fimepinostat: first-in-class suppressor of MYC *There are no drugs currently approved for MYC inhibition* CA-4948: first-in-class suppressor of the TLR Pathway *There are no drugs currently approved that block the entire TLR pathway* CA-170*: first-in-class suppressor of VISTA *There are no drugs currently approved for VISTA inhibition*
Potential Upcoming Milestones	• Further safety data in fimepinostat-venetoclax combination study • Initiation of CA-4948 Phase 1 study in combination with BTK inhibitor • Initiation of CA-4948 Phase 1 study in AML/MDS

**Based on initial data no further patients will be enrolled in the study. We are currently evaluating future studies for CA-170.*

Curis Leadership Team



NASDAQ: CRIS